# 4D pharma plc Directors increase holdings in company

- Link: https://www.directorstalkinterviews.com/4d-pharma-plc-directors-increase-holdings-in-company/412762953
- Published: 2018-12-13T07:28:37+00:00
- Author: Giles Arbor

**4D pharma plc** (LON: DDDD), a pharmaceutical company leading the development 
of Live Biotherapeutics, has today announced that Duncan Peyton, David Norwood, 
Alex Stevenson and Thomas Engelen all Directors in the company have today purchased
ordinary shares in the Company as listed below. Following this transaction, the 
Directors have a resulting interest in the ordinary shares of the Company set out
as follows.

  |

Name

  |   |

Shares in 4D pharma plc before purchase

  |

% of total shares in issue

  |

Shares in 4D pharma plc after purchase

  |

% of total shares in issue

  |  
 |   |   |   |   |   |   |  
 |

David Norwood (Chairman)

  |   |

7,000,000

  |

10.69%

  |

7,050,000

  |

10.76%

  |  
 |

Duncan Peyton (CEO)

  |   |

6,250,286

  |

9.54%

  |

6,337,215

  |

9.68%

  |  
 |

Alex Stevenson (CSO)

  |   |

6,250,286

  |

9.54%

  |

6,337,242

  |

9.68%

  |  
 |

Thomas Engelen (NXD)

  |   |

500,000

  |

0.76%

  |

519,000

  |

0.79%

  |

Founded in February 2014, 4D Pharma plc is a world leader in the development of 
Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as
biological products that contain a live organism, such as a bacteria, that is applicable
to the prevention, treatment or cure of a disease. 4D has developed a proprietary
platform that rationally identifies novel bacteria that have a precise and evolved
therapeutic effect. All of 4D’s Live Biotherapeutic products are orally delivered
single strains of bacteria that are naturally found in the healthy human gut. 4D
has completed a Phase I study in Irritable Bowel Syndrome and has completed dosing
in a Phase I study in Paediatric Crohn’s Disease. It currently has a pipeline of
13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled
asthma, autoimmune and CNS disease, and plans to commence four additional clinical
studies in 2018.

Share on:
